Merck and Bristol-Myers Squibb are key players in cancer treatment. Find out why MRK and BMY stocks have different prospects ...

Oncolytics Biotech faces financial struggles and unclear pelareorep efficacy signals. Learn why ONCY stock's risks outweigh ...

The following is a summary of “Efficacy and safety of PD-1/PD-L1 inhibitor monotherapy or combination therapy versus platinum-based chemotherapy as a first-line treatment of advanced urothelial cancer ...

This expansion will evaluate the combination of Decoy20 with BeiGene’s PD-1 checkpoint inhibitor, tislelizumab, with a focus on safety, dose optimization, and early signs of anti-tumor activity.

This expansion will evaluate the combination of Decoy20 with BeiGene's PD-1 checkpoint inhibitor, tislelizumab, with a focus on safety, dose optimization, and early signs of anti-tumor activity.

PD-1 blockade conferred benefit to certain women with surgically resectable endometrial cancer, findings presented at Society ...

It is the second drug in the PD-1/PD-L1 inhibitor class to be cleared in a subcutaneous injection form by the FDA after Roche's Tecentriq Hybreza (atezolizumab and hyaluronidase) – which got a ...

The company has mid-stage trials of the PD-1 inhibitor on the go as a combination therapy with CSF-1 inhibitor BLZ945 in solid tumours, c-Met inhibitor capmatinib in liver cancer, and Palobiofarma ...

The approval for the first-line treatment of esophageal squamous cell carcinoma comes shortly after a label expansion for the ...

A two-vehicle crash in Waynesboro on Tuesday morning resulted in one fatality and multiple injuries. Brittany J. Comer, 31, of Waynesboro, was killed, police said. The driver of the other vehicle, ...

NEW YORK – Actinium Pharmaceuticals on Tuesday said it will evaluate whether its radiotherapeutic Actimab-A can boost the efficacy of PD-1 inhibitors in PD-L1-expressing solid tumors in a new clinical ...